SCHEMBL3036277

SCHEMBL3036277

CCC([C]=O)C1CCCC1

nearest known ligand 0.46

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.46
EPHX1 P07099 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL741065 0.98 SHBG (0.50) SHBGEPHX1
SCHEMBL12987447 0.98 SHBG (0.50) SHBGEPHX1
SCHEMBL9416078 0.95
SCHEMBL9415959 0.90
SCHEMBL1335896 0.80 SHBG (0.41) SHBGEPHX1
SCHEMBL10542678 0.78 SHBG (0.32) SHBG
SCHEMBL10545326 0.78 SHBG (0.32) SHBG
SCHEMBL6988843 0.77 SHBG (0.39) SHBGEPHX1
SCHEMBL6592010 0.76 SHBG (0.46) SHBGEPHX1
SCHEMBL14509959 0.76 SHBG (0.46) SHBGEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023085402-A1 PEPTIDE HAVING INHIBITORY ACTIVITY ON FORMATION OF LEUKOCYTE EXTRACELLULAR TRAPS 平橋 淳一 2023-05-19 WO disclosed
US-11566047-B2 Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) 2023-01-31 US disclosed
US-20190177370-A1 PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES (JP) 2019-06-13 US disclosed
EP-1745002-B1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE HIGH POINT PHARMACEUTICALS LLC (US) 2010-11-03 EP disclosed
US-20100210653-A1 Novel Compounds, Their Preparations and Use HIGH POINT PHARMACEUTICALS, LLC (US) 2010-08-19 US disclosed
US-20080114036-A1 Novel Compounds, Their Preparations And Use NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
EP-1745002-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2007-01-24 EP disclosed
WO-2005105725-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed
EP-0599265-A1 Antibacterial, antifungal compound and its production method Takeda Chemical Industries, Ltd. (JP) 1994-06-01 EP disclosed
US-4097496-A ANTIPROSTAGLANDIN ACTIVITY HOECHST AKTIENGESELLSCHAFT (DT) 1978-06-27 US disclosed
US-4083990-A ANTIPROSTAGLANDIN EFFECT HOECHST AKTIENGESELLSCHAFT (DT) 1978-04-11 US disclosed
US-4061766-A PROSTAGLANDIN ANTAGONIST HOECHST AKTIENGESELLSCHAFT (DT) 1977-12-06 US disclosed
US-3984459-A ANTI-PROSTAGLANDINS HOECHST AKTIENGESELLSCHAFT (DT) 1976-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190177370-A1 PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF MYOF, MSTN, VIP SHBG 661/4885EPHX1 4726/4885
US-20100210653-A1 Novel Compounds, Their Preparations and Use PPARG, PPARD, PPARA SHBG 718/4885EPHX1 1901/4885
US-11566047-B2 Peptide or pharmaceutically acceptable salt thereof, or prodrug thereof MYOF, MSTN, VIP SHBG 661/4885EPHX1 4726/4885
US-20080114036-A1 Novel Compounds, Their Preparations And Use PPARG, PPARD, GPR119 SHBG 595/4885EPHX1 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.